ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors

Background: Pancreatic ductal adenocarcinoma (PDAC) has limited standard of care therapeutic options. While initially received with enthusiasm, results from targeted therapy with small molecule tyrosine kinases inhibitors (TKIs) have been mixed, in part due to poor patient selection and compensatory...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Theranostics
Autori principali: Escorcia, Freddy E., Houghton, Jacob L., Abdel-Atti, Dalya, Pereira, Patricia R., Cho, Andrew, Gutsche, Nicholas T., Baidoo, Kwamena E., Lewis, Jason S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ivyspring International Publisher 2020
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6929627/
https://ncbi.nlm.nih.gov/pubmed/31903112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.37098
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi